.ppt_第1页](http://file.renrendoc.com/FileRoot1/2019-12/23/820fa69b-2fed-4d1e-8a7b-9507662745bc/820fa69b-2fed-4d1e-8a7b-9507662745bc1.gif)
.ppt_第2页](http://file.renrendoc.com/FileRoot1/2019-12/23/820fa69b-2fed-4d1e-8a7b-9507662745bc/820fa69b-2fed-4d1e-8a7b-9507662745bc2.gif)
.ppt_第3页](http://file.renrendoc.com/FileRoot1/2019-12/23/820fa69b-2fed-4d1e-8a7b-9507662745bc/820fa69b-2fed-4d1e-8a7b-9507662745bc3.gif)
.ppt_第4页](http://file.renrendoc.com/FileRoot1/2019-12/23/820fa69b-2fed-4d1e-8a7b-9507662745bc/820fa69b-2fed-4d1e-8a7b-9507662745bc4.gif)
.ppt_第5页](http://file.renrendoc.com/FileRoot1/2019-12/23/820fa69b-2fed-4d1e-8a7b-9507662745bc/820fa69b-2fed-4d1e-8a7b-9507662745bc5.gif)
已阅读5页,还剩30页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
pharmaceuticaldevelopmentwithfocusonpaediatricformulations who fiptrainingworkshophyattregencyhotelsaharairportroadandherieast mumbai india28april2008 2may2008 pharmaceuticaldevelopmentwithfocusonpaediatricformulations presentedby name peteryorkcontactdetails p york bradford ac uk pharmaceuticaldevelopmentwithfocusonpaediatricformulations dosageformdesignandmanufacture inthispresentation designofpaediatricmedicines underlyingprinciplescriticalfactorsrelatedtoapi s propertiesformulationandmanufacturingplanfactorsforformulationselectionanddesignchallengesfor forwardthinking withpaediatricmedicines medicinalproducts activecompound api medicine molecules qualitymacromolecule safety efficacyexcipientsmanufacture medicinalproducts physicaladministrationrequiredpatientformroutetimeofageonsetaction periodofdrugdeliverysolidsoralsecondspreterminfantssemi solidsparenteralminutesterminfants 0 28days liquidstopical rectalhoursinfants toddlers 28days 23months respiratorydayschildren 2 11yrs eye earweeks adolescents 12 16 18yrs monthsadults designofmedicines primaryfactorstoconsiderapiproperties e g solubility absorptioncharacteristics bcs stability dose routeofadministration linkedtoapipharmacology therapeutics pharmacokinetics intendedpatientpopulation ageetc selectionoftypeofdosageform linkedtoselectionoffunctionalexcipients awarenessofmanufacturingprocess gmp efficiency exposuretomanufacturing stresses sourcingofqualityapisandexcipients paediatricmedicinesandspecificdosageforms solidspowders granules pelletscapsules dpis implantstablets dispersibletablets bilayertabletssemi solidssuppositoriesdermatologicalsliquidssyrups solutions suspensionspareteralsmdis focus paediatricmedicines hiv aids malariaandtb solidspowders granules pelletscapsules dpis implantstablets dispersible bilayer chewable bufferedsemi solidssuppositoriesdermatologicalsliquidssyrups solutions suspensionsparenteralsmdis paediatricmedicinesforhiv aids malariaandtb additionalissues continuouschangesofmedicinedispositionalparametersdose adme pk doseratiosforfixeddosecombinations fdcs extemporaneous dispensing egdilutions fractioning ofadultdosageform packaging stability compliancestability transportchallengesforliquidformulations whomodellistofessentialmedicinesforchildren oct2007 antituberculosismedicinesethambutol oralliquid 25mg ml tablet 100mg 400mg isoniazid oralliquid 50mg 5ml tablet 50mg scored 100mg 300mg pyrazinamide oralliquid 30mg ml tablet 150mg dispersible scored 400mg rifampicin oralliquid 20mg ml capsuleandtablet 150mg 300mg rifampicin isoniazid pyrazinamide tablet60mg 30mg 150mgstreptomycin powderforinjection 1g assulphate invial whomodellistofessentialmedicinesforchildren oct2007 intendedforchildrenupto12yearsofagecorelist minimummedicineneedsforabasichealthcaresystemspecializedlist essentialmedicinesforprioritydiseasesforwhichspecializeddiagnostic monitoring specialistmedicalcare and orspecialisttrainingareneededhttp www who int medicines publications essentialmedicines en index html whomodellistofessentialmedicinesforchildren october2007 antiretrovirals subcommitteerecommendsandendorsestheuseoffixed dosecombinationsandthedevelopmentofnewfixed dosecombinations includingmodifieddosageforms non refrigeratedproductsandpaediatricdosageformswithassuredpharmaceuticalquality nucleoside nucleotidereversetranscriptaseinhibitorsegabacavir oralliquid 100mg 5ml assulphate tablet 300mg assulphate egdidanosine bufferedpowderfororalliquid 100mg 167mg 250mgpackets capsule unbufferedenteric coated125mg 200mg 250mg 400mg tablet buffered chewable dispersible25mg 50mg 100mg 150mg 200mg nonnucleotisidereversetranscriptaseinhibitorsegefavirenz capsule 50mg 100mg 200mg oralliquid 150mg 5ml tablet600mgproteaseinhibitorsegritonavir oralliquid 400mg 5ml oralsoliddosagefom 100mg whomodellistofessentialmedicinesforchildren oct2007 antiretroviralsfixeddosecombinations fdc stavudine lamivudine nevirapine tablets 30mg 150mg 200mg zidovudine lamivudine tablets 300mg 150mg zidovudine lamuvidine nevirapine tablets 300mg 150mg 200mg whomodellistofessentialmedicinesforchildren oct2007 antimalarialmedicinesforcurativetreatment medicinesforthetreatmentofp falciparummalariacasesshouldbeusedincombination thelistcurrentlyrecommendscombinationsaccordingtotreatmentguidelines thesubcommitteerecognizesthatnotallofthesefdcsexistandencouragestheirdevelopmentandrigoroustesting thesubcommitteealsoencouragesdevelopmentandtestingofrectaldosageforms egamodiaquine tablet 153mgor200mg ashcl tobeusedincombinationwithartesunate50mgdoxycycline capsule 100mg ashcl tablet dispersible100mgasmonohydrate foruseonlyincombinationwithquininequinine injection 300mg ashcl mlas2mlampoule tablet 300mg assulphateorbisulphate usedincombinationwithdoxycycline criticalfactorsrelatedtoapi s properties activepharmaceuticalingredient s sourcing patentedandgenericcompoundsspecificationsandstandardspharmacopoeialmonographs bp usp ip ep referencestandardsfocusonchemicalidentificationandpurityincreasingawarenessofneedtomonitorphysical crystallographicand functional propertiesothersourcesofinformation scientificliterature www innovatorproductinformation apiroutinetesting goodpractice provideassuranceofqualityandsafetyverificationofcoaandmagnitudeoftestingprogrammesamplingprogramme isolatedquarantinestorageareasretention storageofbatchsamplestrainingprogrammesforstaff sops glpandvalidationofmethods confidence inconsistentqualityofsupplyfromchosensuppliers apiproperties formulationdesignandprocessing 1 50 ofnewapis andmanyothers haveverylowaqueoussolubilitywhichcanconstraindrugdissolution ierateofsolution andtherebylimitbioavailabilitymanyapisexhibitpolymorphism alsosolvation hydration alternativemolecularpackingofthesamechemicalincrystallinematerialleadingtodifferentpropertiessuchasdissolutionrate moisturecontentcontrol hygroscopicmaterialoftendifficulttoprocess egtabletting changeinhydrationstate egduringwetgranulation respiratorydrugdelivery dpisandsuspensionmdisrequiredrugparticlesize aerodynamic of1 5micronsallabovearealsoexamplesofqualityissueswhenformulatingandprocessingapis mayrequireadditionaltestingand orcontrolprocedures apiproperties formulationdesignandprocessing 2 additionalvalidatedtestingmethodsmayberequiredtoguideanddirectformulationdesign e g phsolubilityprofilepharmacopoeianowintroducinggeneralguidancechapters information testingmethods propertiesbeingintroducedincludeparticlesizing laserlightdiffractionmethod crystallinity byx raypowderdiffraction amorphouscontent byx raypowderdiffraction wettability byliquidpenetratingmethods apiproperties particlesize manysubstancespoorlyaqueoussoluble bcsclassiiandiv reduceparticlesizetomaximisedissolution alsoforbcsclassiii suchcompoundsroutinelymicronised potentialforchemicalandcrystallographicdamagewhichcancompromisestabilityandintra andinter batchconsistencypotentialissuesforliquidsuspensionformulations egparticlesizechangesonstability apiproperties polymorphism e gcarbamazepine ritonavir representationoftwopolymorphicformsofacrystalconsistingofamoleculerepresentedbya hockey stick shape ritonavir issueofpolymorphism ritonavir originatorabbott hivproteaseinhibitornorvirproductintroducedin1996as semi solid capsulepreparationcontaininga solid solution ofdruginpegsummer1998 capsulesuppliesthreatenedasanewmuchlesssolublecrystalformofritonavirprecipitatedinthecapsuledrugdissolutionwassloweddown compromisingbioavailabilityproductwaswithdrawnandreformulatedinsoftelasticcapsuleformwithnewformofritonavir bauretal pharmres18 6 859 866 2001 apiproperties formulationdesignandprocessing 3 alternativepre treatmentandprocessingofapis egalternativefinalsolventusedduringfinalcrystallisationstepduringsynthesisofapi useofcrystallisationratherthanmillingprocessforparticlesizereduction canleadtodifferentsurfacepropertiesofparticles suchasinterparticlecohesionandsurface charge thesephenomenacanleadtodifferentsecondaryprocessingbehaviourandpotentiallyvariationinproductperformance apiproperties characteristicstobeconsideredwhenformulatingmedicines apipropertyclassification inter dependenciesbetween groupings formulationandmanufacturingplan developmentpharmaceutics designofapaediatricdosageform 1 defineapi s anddosageregimeconsider routeofadministration suitabledosageformwhatarepharmacokineticdeterminerelevantpropertiesofcharacteristicsofapi s api s t50 cmax auc physicochemical crystallographicbcs fororalproducts stabilityunder stress conditionsba bdissue compatibilitywithsecondapiand orcommonexcipientselectdosageformandstrength developmentpharmaceutics formulationandmanufacturingplan designofapaediatricdosageform 2 selectiondosageformandstrengthconsidersuitableformulationsandmanufacturingprocessesprototypeformulationsandmanufacturingroute andprototypepackagingoptimisationtechniquesvalidation formulationandmanufacturingprocess selectionfinalformulation define designspace processcontrol sourcesofinformationinnovatorliteraturecompanyexperienceotherliteraturesources testingphys chemstability dissolution relevantproducttests pilotbestudy doeaitools designofapaediatricdosageform selectfinalformulation manufacturingprocessandpackagingprocessscale upstudies batchesconfirmatorystability dissolution studies bestudy documentationforprequalification registrationdossiers factorsinfluencingformulationselectionanddesign paediatricmedicines liquidformulations solutions syrups preferablyavoidsugarandalcoholinformulations drugsolubility dose volume stability ph api s compatibilitywithvehicle liquiddiluents taste tastemasking colour flavour singledosevsmultidose preservativesetc suspensions andliquidsproductsreconstitutedfrompowders granules asabove viscosity api s particlesedimentationvolume redispersion suspending flocculatingagents particlesize crystallinitychangesonstorage shelflife paediatricmedicines solidformulations api s compatibilitywithexcipients otheractive s needtoseparateapis selectionof appropriate functionalexcipientsapidoseand orphysicochemicalpropertiesmaydirectselectionofmanufacturingroute egdirectcompressionforlowdoseproducts heat lightsensitiveapis keyproductperfo
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2024秋八年级英语上册 Unit 4 What's the best movie theater Section A(1a-2d)说课稿(新版)人教新目标版
- 店铺转让的合同
- 2025版一年期租房合同范本:一年房屋租赁合同模板
- 水果采购合同
- 新教材高中化学 1.2.2 离子反应说课稿 新人教版必修1
- 技术开发委托合同
- 苏州市劳动合同5篇
- 2025翡翠交易合同范本
- 2025年股权让与反担保合同
- 考点解析人教版八年级上册物理《机械运动》专题测试试题(含详细解析)
- 2025年机械工程师职称考试题及参考答案
- 护理专业科普
- EHS风险管理监测规范制定
- Unit 2 We are Family.单元测试( 含答案)2025-2026学年人教版(2024)英语七年级上册
- 2025“文化强国杯”全国高校文学知识挑战赛备赛试题库150题(含答案)
- 一科一品护理服务
- 中燃集团工程物资供应商管理制度
- 小学食品安全培训课件
- 项目立项申请表
- 机械基础 第2版 习题答案
- 2025发展对象考试题库附含答案
评论
0/150
提交评论